Self-reported cognitive dysfunction and memory impairment in Systemic Autoimmune Rheumatic Diseases (SARDs): a mixed methods analysis of the INSPIRE cohort
No Thumbnail Available
Authors
Varshney A.
Pollak T.A.
Arunasalam A.
Massou E.
Naughton F.
Bourgeois J.A.
Calderwood L.
Leschziner G.
Bortoluzzi A.
Tunks A.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
Objectives To explore self-reported cognitive dysfunction, including memory impairment, across systemic autoimmune rheumatic diseases (SARDs) and examine its impact and associations with demographic, clinical and psychosocial factors. Methods A mixed-methods approach was employed, surveying 1853 SARD patients and 463 controls using validated instruments including the Everyday Memory Questionnaire-Revised (EMQ-R). Kruskal-Wallis tests and Spearman's rank correlations were used to compare the groups. Additionally, 67 in-depth interviews were conducted for qualitative thematic analysis. Results Systemic lupus erythematosus (SLE), undifferentiated connective tissue disease (UCTD) and Sjogren's patients reported significantly higher rates of memory impairments than other groups. There was no evidence of increased self-reported memory impairment with disease duration or age. Moderate positive associations were found between EMQ scores and the lifetime frequency of all other neuropsychiatric symptoms. EMQ-R was positively associated with self-assessment of overall disease activity (r=0.291, P 2 = 0.159). Expanding on the quantitative findings, qualitative analyses highlighted the adverse impact of cognitive dysfunction on daily participation in activities, social isolation, self-esteem and mental well-being, and the potential underreporting of these symptoms to clinicians. Conclusion This study highlights a significant impairment of memory in SARDs, notably in SLE, UCTD and Sjogren's, and the impact of cognitive impairment on daily lives and well-being. The positive associations with disease activity and neuropsychiatric symptoms, and negative association with well-being emphasizes the need for targeted interventions. Future research should prioritize developing pharmacological and psychosocial interventions to address cognitive dysfunction in SARD patients. While reassuringly there was no evidence of worsening memory impairment over time, the underreporting of symptoms also suggests that cognitive issues may be more prevalent than clinical records indicate and thus emphasize the importance of thorough patient assessment. Copyright © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Description
Citation
Publisher
License
Journal
Rheumatology
Volume
64
Issue
12